Published in Pediatr Infect Dis J on June 01, 2002
Randomized controlled comparison of ofloxacin, azithromycin, and an ofloxacin-azithromycin combination for treatment of multidrug-resistant and nalidixic acid-resistant typhoid fever. Antimicrob Agents Chemother (2006) 2.01
Epidemiology, Clinical Presentation, Laboratory Diagnosis, Antimicrobial Resistance, and Antimicrobial Management of Invasive Salmonella Infections. Clin Microbiol Rev (2015) 1.48
Ciprofloxacin safety in paediatrics: a systematic review. Arch Dis Child (2011) 1.07
Susceptibilities to levofloxacin in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis clinical isolates from children: results from 2000-2001 and 2001-2002 TRUST studies in the United States. Antimicrob Agents Chemother (2003) 0.96
Typhoid Fever. Curr Infect Dis Rep (2004) 0.95
The effect of fluoroquinolone antibiotics on growing cartilage in the lamb model. J Pediatr Orthop (2009) 0.82
Safety Concerns Surrounding Quinolone Use in Children. J Clin Pharmacol (2016) 0.78
Drug dosage in children with reduced renal function. Pediatr Nephrol (2005) 0.78
Options for treating resistant Shigella species infections in children. J Pediatr Pharmacol Ther (2008) 0.78
Pharmacokinetics and Safety of Ofloxacin in Children with Drug-Resistant Tuberculosis. Antimicrob Agents Chemother (2015) 0.77
Current ciprofloxacin usage in children hospitalized in a referral hospital in Paris. BMC Infect Dis (2013) 0.75
Estimated number of prevalent cases of metastatic bone disease in the US adult population. Clin Epidemiol (2012) 1.42
Comparative safety profile of levofloxacin in 2523 children with a focus on four specific musculoskeletal disorders. Pediatr Infect Dis J (2007) 1.41
Usability testing of an online self-management program for adolescents with juvenile idiopathic arthritis. J Med Internet Res (2010) 1.36
Comparative study of levofloxacin in the treatment of children with community-acquired pneumonia. Pediatr Infect Dis J (2007) 1.35
The increased incidence of pure red cell aplasia with an Eprex formulation in uncoated rubber stopper syringes. Kidney Int (2005) 1.31
Probability of target attainment for ceftobiprole as derived from a population pharmacokinetic analysis of 150 subjects. Antimicrob Agents Chemother (2007) 1.29
Economic impact of juvenile idiopathic arthritis. Arthritis Rheum (2007) 1.20
Anti-MRSA beta-lactams in development, with a focus on ceftobiprole: the first anti-MRSA beta-lactam to demonstrate clinical efficacy. Expert Opin Investig Drugs (2007) 1.10
Achilles tendon rupture and its association with fluoroquinolone antibiotics and other potential risk factors in a managed care population. Pharmacoepidemiol Drug Saf (2006) 1.09
Effect of ciprofloxacin on lethal and sublethal challenge with endotoxin and on early cytokine responses in a murine in vivo model. J Antimicrob Chemother (2002) 1.08
Factors associated with the use of complementary and alternative medicine in juvenile idiopathic arthritis. Arthritis Rheum (2004) 1.08
Identifying exposure targets for treatment of staphylococcal pneumonia with ceftobiprole. Antimicrob Agents Chemother (2009) 1.07
Summary of worldwide pediatric malignancies reported after exposure to etanercept. Pediatr Rheumatol Online J (2010) 1.03
Susceptibilities to levofloxacin in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis clinical isolates from children: results from 2000-2001 and 2001-2002 TRUST studies in the United States. Antimicrob Agents Chemother (2003) 0.96
Long-term open-label preliminary study of the safety and efficacy of leflunomide in patients with polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum (2005) 0.93
A randomised, double-blind trial comparing ceftobiprole medocaril with ceftriaxone with or without linezolid for the treatment of patients with community-acquired pneumonia requiring hospitalisation. Int J Antimicrob Agents (2012) 0.91
Levofloxacin pharmacokinetics in children. J Clin Pharmacol (2005) 0.91
Population pharmacokinetic analysis of ceftobiprole for treatment of complicated skin and skin structure infections. Antimicrob Agents Chemother (2008) 0.90
Pharmacometrics-based dose selection of levofloxacin as a treatment for postexposure inhalational anthrax in children. Antimicrob Agents Chemother (2009) 0.88
Chronic inflammatory arthritis prevalence estimates for children and adolescents in three Canadian provinces. Rheumatol Int (2014) 0.85
Clinicopathological study of the WHO classification in childhood lupus nephritis. Pediatr Nephrol (2004) 0.83
Pharmacodynamic profiling of ceftobiprole for treatment of complicated skin and skin structure infections. Antimicrob Agents Chemother (2009) 0.83
An open-label, double tympanocentesis study of levofloxacin therapy in children with, or at high risk for, recurrent or persistent acute otitis media. Pediatr Infect Dis J (2006) 0.82
Children's medicines in Tanzania: a national survey of administration practices and preferences. PLoS One (2013) 0.81
The prevalence of systemic autoimmune rheumatic diseases in Canadian pediatric populations: administrative database estimates. Rheumatol Int (2014) 0.79
Characterization and dynamics of middle ear fluid and nasopharyngeal isolates of Streptococcus pneumoniae from 12 children treated with levofloxacin. Antimicrob Agents Chemother (2007) 0.76
Prevalence of patients with nonmetastatic prostate cancer on androgen deprivation therapy in the United States. Urology (2013) 0.76
Renal impairment, hemoglobinuria, and hemoglobinemia among patients with idiopathic thrombocytopenic purpura. Am J Hematol (2011) 0.75
Estimating high-risk castration resistant prostate cancer (CRPC) using electronic health records. Can J Urol (2015) 0.75
Treatment of painful accessory navicular: a modification to simple excision. Foot Ankle Spec (2008) 0.75